How well does Enasidenib(Idhifa) work?

This section summarizes the clinical effectiveness of IDHIFA as observed in a pivotal study.

Clinical Effectiveness

In a clinical trial of 199 adult patients with relapsed or refractory IDH2-mutant AML, treatment with IDHIFA resulted in a combined complete remission (CR) and complete remission with partial hematologic recovery (CRh) rate of 23%. The median duration of these responses was 8.2 months. Furthermore, 34% of patients who were transfusion-dependent at baseline achieved transfusion independence during treatment.